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DR Congo is currently facing its tenth
outbreak of Ebola virus disease (EVD)
since the virus was discovered in
1976. As of March 3, 2019, there were
897 confirmed cases, with 563 deaths
(including confirmed and probable
deaths). 1 Although potentially
effective ring vaccination trials have
been integrated into the response
against EVD, the risk of further
propagation of the outbreak remains
high. The virus has spread to densely
populated urban areas, and parts of
the country where optimal surveillance
and health-care delivery are dangerous
and sometimes interrupted due to the
presence of armed groups.
Since the mortality in individuals
with EVD is high (around 50%) 2,3
and no effective pharmacological
treatments have been identified, many
patients with EVD will die, even in the
best circumstances. In October, 2017,
the Lancet Commission on palliative
care4 pointed out that palliative care
has been largely ignored, especially for
the most vulnerable populations and
those living in humanitarian crises.
In The Lancet, François Lamontagne
and colleagues5 highlighted just how
entrenched the problem is.
Although Lamontagne and col
leagues’ guidelines stress the impor
tance of supportive and psychosocial
care to alleviate the burden of suffering
and severe distress associated with EVD,
these guidelines do not acknowledge
the value of this care for all patients
regardless of outcome, even death.
This is consistent with other published
recommendations for EVD patient
management.5,6
The value of these guidelines
is clear: to facilitate faster and
more standardised care informed
by a synthesis of existing (albeit
limited) evidence on what is most
likely to help patients affected by
EVD. Nevertheless, until curative

treatments for the management of
EVD are available, clinical guidelines
and specific protocols for EVD
must include clear recommendations
and instructions on the integration
of palliative care into the delivery
of optimum care for patients with
suspected and confirmed EVD.
Guidelines on palliative care for
EVD need to be clearly defined so
that its value and place in highfatality humanitarian crises can
begin to gain practical traction
and acceptability. Clearly defined
guidelines on palliative care would
also legitimise training and dialogue
on palliative care in contexts where
staff have no previous experience
treating patients with EVD.6
Palliative care and pain relief are
essential elements of universal health
coverage,4 but much more should be
done to make it part of any health
intervention. A first step is to ensure
that health professionals, patients,
and families understand that palliative
care can improve patient quality of life
and prevent and alleviate suffering.
Ensuring that palliative care gets
explicitly integrated into guidelines
for care of critically ill people, including
but not limited to patients with EVD, is
of equal importance.
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